BVT Knock-Out ABBV/ DE000VM6U8V4 /
6/18/2024 4:39:52 PM | Chg.+0.27 | Bid4:53:55 PM | Ask4:53:55 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.86EUR | +16.98% | 1.79 Bid Size: 20,000 |
1.80 Ask Size: 20,000 |
AbbVie Inc | 153.20 USD | 12/31/2078 | Call |
GlobeNewswire
2:00 PM
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...
GlobeNewswire
12:13 PM
CEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoi...
GlobeNewswire
6/17
Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, B...
GlobeNewswire
6/15
CEREVEL STOCK NOTICE: Think $45 Per Share is Too Low for Cerevel (Nasdaq: CERE)? Contact BFA Law abo...
GlobeNewswire
6/13
Anima Biotech to Present at the Society for Medicines Research’s Modulating RNA with Oligonucleotide...
GlobeNewswire
6/13
CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investi...
GlobeNewswire
6/13
What Employees at the Fortune Best Workplaces in New York, Chicago, Texas, and the Bay Area Value Mo...
GlobeNewswire
6/12
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, ...
GlobeNewswire
6/12
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in ...
GlobeNewswire
6/11
CEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urg...
GlobeNewswire
6/8
CEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into ...
GlobeNewswire
6/5
CEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law abou...
GlobeNewswire
6/5
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...
GlobeNewswire
6/4
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
6/3
ACQUISITION NEWS: Cerevel’s (Nasdaq: CERE) $45 Merger Offer is Being Investigated for Being Too Low,...